Replies to post #142377 on Innovation Pharmaceuticals Inc (IPIX)

[F1ash]

"BEVERLY, MA–(Marketwired – January 21, 2016) - Cellceutix Corporation (OTC: CTIX) (the “Company”), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that today we received the letter from the U.S. Food and Drug Administration (FDA) granting Orphan Drug Designation to Kevetrin for the treatment of pancreatic cancer. - See more at: http://cellceutix.com/cellceutix-receives-fda-orphan-drug-designation-for-kevetrin-for-the-treatment-of-pancreatic-cancer/#sthash.Kfrnd4Yb.dpuf

[MinnieM]

$CTIX - FDA designations:

3 Orphans, 1 QIDP, 1 Fast-track and 1 Rare-Pediatric

Orphan: Pancreatic, Ovarian, Retinoblastoma

QIDP: Brilacidin

Fast-track: Oral Mucositis (OM)

Rare-Pediatric: Retinoblastoma